Market research
MWG.F InMed Pharmaceuticals Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.98
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- CA4576377002
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.98
About
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MWG.F discussion.
5 years, 6 months ago
InMed Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 19.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
InMed Pharmaceuticals Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 33.0% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 35.7% to $-2M since the same quarter in the previous year.
Based on the above factors, InMed Pharmaceuticals Inc gets an overall score of 3/5.